Member Info for Hulver

Once upon a time there was a CBR being tested for the below:

https://www.bbc.co.uk/news/articles/ckg2xyyj9w5o

Perhaps it's a side-effect discovered in the trial!

So what happened to this? And why haven't the board provided an update with the RNS on shares in issue today?

https://www.lse.co.uk/rns/HEMO/strategic-investment-from-prevail-partners-llc-re84v9fv90tzezc.html

Work delayed? Work done and creditor? Work shelved? - no news today seems not to be good news in this case.

Moors, in legal terms parties 'execute' a contract/agreement.

I don't recall this report being shared on here (apologies if it was), but this is the sort of outcome/report that we will be aiming for, perhaps SOON- just three weeks to live when treated and declared cancer free three months later.

https://www.bbc.co.uk/news/articles/cq64jpg3921o

Go HEMO CAR-T. Anyone else thinking we may be approaching the next expansion stage?

JD the Master Tortoise

MP the Mock Turtle

"Will you, won't you, will you

Won't you, will you join the dance?"

Hopefully the orphan drug designation request was submitted at the commencement of the trial.

HT, HH - thanks for your replies.

And of course Vlad was presenting on CBR at RESI Boston 2023 re: plan for Bait Biotechnology spin out, with Prevail there promoting Hemo too (shortly after their initial investment).

We must be due a CBR update soon too, with the outcomes from in vivo testing, and hopefully next steps. I think the last we were told was that CBR will move forward once funding is made available.

The annual report is not that far off now, due end April, and they will need to satisfy auditors re: going concern.

It would be interesting to see the share register now versus what it was pre- Prevail's involvement. I meant to look into how to request a register as I think it should be available to shareholders on request. Whilst beneficial shareholdings can be disguised behind company names, I think it may be quite telling.

I still think this Prevail Partners fund investor is very interesting though.

Whose money are they investing? Who are the shareholders in Prevail Partners investment, or possibly the cell of it that is invested in Hemo if it has a separate cell per investment.

Though they may be entirely coincidental, some common but strange things about Prevail's investments/investee companies include:

(i) they invest at a premium - if you were an investor in a fund you would expect the fund manager to be making a return for you - doesn't it seem strange that Prevail's directors are happy to invest their clients' monies at a significant premium (thereby taking an immediate loss). How do they explain that to their investors? I doubt Micky would be happy with that investment strategy (as a standalone strategy).

(ii) Subscription proceeds flow back to a related company, Prevail Infoworks, as payment for work done (a related company - that seems to be a conflict of interest, which Prevail investment fund shareholders must be comfortable with).

(iii) the use of a share consolidation to reduce shares/increase share price, perhaps making it less attractive to private investors

(iv) good news released, followed by placings at significant discounts - and in Hemo's case subsequent recognition that some 'investors' were actually shorting the shares on such news seemingly knowing that they would be allocated new shares at the signficantly discounted issue price.

Another strange thing that seemed to coincide with some of this activity was the switch to SETS - and the automated trades that started to happen Feb/Mar 24 around the time of the FDA IND clearance .

Then I would query, did Hemo approach Prevail, or did another party direct Hemo to use Prevail (and perhaps MDA).

We still don't know why Vlad cannot refer to first trial centre by name (even though he did name them in end October RNS last year relating to Prevail's second investment).

All quite strange behaviour - not least the share price.

A further 11,666 shares to be issued by end of next week (at a price in old money of $0.075; which in new money is $30 per share) per the 2nd October 2024 RNS (extract below) - this will not inject new cash but is essentially paying for work undertaken to be ready for the commencement of the AML pediatric study.

"Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that Prevail Partners, LLC ("Prevail Partners"), an investment fund, has agreed to invest a total of $350,000 (approximately £269,000) in the Company through a subscription for ordinary shares in the Company at a price of US$0.075 per share (approximately 5.6p). This follows a similar investment in the Company by Prevail Partners announced on 18 September 2024. The subscription price represents a premium of approximately 275% to the Company's closing share price on 1 October 2024.

The subscription will take effect in March 2025 ahead of the planned HEMO-CAR-T pediatric study. This will follow the initiation of the adult clinical trial in HEMO-CAR-T at the MD Anderson Cancer Center, Texas, which is expected to commence later this year. The agreement governing the subscription contains customary warranties from the Company and Prevail Partners."

And a price of $30 per share (approx £23) now equates to a premium of approximately 1200% to today's closing share price.

So who is really behind this Prevail Partners investment fund, and how is it structured?

Interesting new research article on role of FLT3 in AML and also referencing evidence of resistance to FLT3 inhibitors and still poor outcomes using them.

https://www.researchgate.net/publication/389984051_Multi-omics_integration_reveals_immune_hallmarks_and_biomarkers_associated_with_FLT3_inhibitor_sensitivity_in_FLT3-mutated_AML

A new solution is till needed! I recollect Hemo doing some work with Completeomics (?) two or three years ago.

We need a HEMO CAR-Tuna - to stop the tuna.

Come on team Hemo, you can do it.

Hey, very happy, day 22 and our clinical trial is showing as 'still recruiting' for P2.

I ask myself five times YoYoYoYoY are some people going to such lengths to disrupt this board and share price - is it because this is the only way they have to try to influence shareholders - shareholders not on bulletin boards are probably inaccessible to them? They clearly think it's worth their time or they do it for entertainment; or maybe they are just AIMOs - the one thing I can't believe from the words they use is that they have any concern for other shareholders.

Enjoy the weekend folks, lots of attempts to cure this ailment never got this far. We are inching closer.

Well if things are progressing well the following subscription is due to happen by the end of March to start work on the pediatric study.

Extract from 2nd October 2024 RNS - Institutional Investment from Prevail Partners:

"The subscription will take effect in March 2025 ahead of the planned HEMO-CAR-T pediatric study. This will follow the initiation of the adult clinical trial in HEMO-CAR-T at the MD Anderson Cancer Center, Texas, which is expected to commence later this year. The agreement governing the subscription contains customary warranties from the Company and Prevail Partners.

The Company's wholly owned subsidiary, Hemogenyx Pharmaceuticals LLC, has also signed an amendment to the Master Service and Technology Agreement ("MSTA"), (the "Amendment") with Prevail InfoWorks, Inc. ("InfoWorks"), the Philadelphia, PA based Clinical Research Organization ("CRO"), and affiliate of Prevail Partners. Infoworks is already contracted by the Company in relation to the existing planned HEMO-CAR-T clinical trials in adult patients.

Under the terms of the Amendment, InfoWorks is to provide clinical services and technologies for the Company's upcoming Phase I study of its anti-FLT3 chimeric antigen receptor-redirected T cells ("CAR-T cells") in pediatric subjects with relapsed/refractory acute myeloid leukemia (AML) and a subset of acute lymphoblastic leukaemia (ALL). The Amendment will come into effect in March 2025.

Services to be provided under the terms of the Amendment include clinical site coordination, project management, data management, clinical monitoring, and pharmacovigilance (safety management) services, and the use of InfoWorks' integrated real-time data analytics platform, the Single Interface®, for clinical support and real-time data analysis. The MSTA has an initial term of 26 months, and Hemogenyx Pharmaceuticals LLC has agreed an initial statement of works relating to the Phase I pediatric AML/ALL study. The pediatric study is expected to commence in the first half of 2025.

The subscription funds received from Prevail Partners will in large part defray the payment made by the Company for the first stage of the work to be undertaken by InfoWorks under the Amendment."

This week's fund raise was stated as being for the adult. I wonder what the warranties are and whether this pediatric study is still going ahead? Hopefully we find out with the subscription by end March.

No, I'd just like to see four other fit and proper directors on the board, with complementary skillsets and experience; then they all need to undertake their directorship responsibilities - as the shareholders of any company should expect.

They may be savings costs with the current board composition but shareholders have had increased risk exposure because of it, and shareholders are suffering for several years now. I'm not sure this week's fund raise was that big an issue, if the results coming out at day 14 are very good it's possibly the best decision, but I am concerned that if there is a big decision to make soon, the board...........! Well they should have the experience necessary, but the past debacles with Mint and these broker short selling fund raises do not fill me with confidence.

Ultimately though Vlad still wants to be a scientist, solve problems that noone else has been able to, and be recognised by the Karolinska Institutet - his best chance of pursuing that drive is to ensure that Hemo is a success via HG-CT-1 to generate the funds he needs to continue his work on CBR etc. So in a sense his and shareholders interests ought to be aligned - I'd just like to see the corporate governance risk exposure reduced significantly.

We not long ago had a change of company secretary - guess they no longer wished to be associated with this corporate governance set up. The new company secretary is a regulated entity for anyone wanting to make a formal complaint that they will be obliged to answer - seemingly the board have not the courtesy to talk to shareholders (except when they want there consolidation resolution passing). We are back now in teh position they were trying to leave behind - didn't take long. Appalling communication and yet again governance.

Minimum of two board changes needed (to remove the conflicted as well), would agree with new input - and I'd expand the board further to have at least one of the team of senior scientists on the board too, I reckon they would have taken far more care in their decision making for the company.

As we are only just hovering above the conversion price of 3p I expect it will have little impact

Two things from the last RNS:

'Further updates on the clinical trial will be provided in the near future.'

'This conversion is expected to take place on or shortly after 8 March 2025.'

I would have expected confirmation of the loan note conversion today - is there a delay, if so why? I expect that holding a convertible loan note is less risky than holding shares at this point.

There a similarities between Hemo's SP trajectory and that of (at least) two other investee companies that Prevail Partners LLC have invested in, in both cases at a premium to the SP at the time.

Take a look at Briacell Therapeutics (their subscription at $8.63 in May 2023) and more recently TNF Pharmaceuticals both have suffered similar decimation of share price to Hemo subsequent to the premium subscriptions by Prevail (yet Prevail are experts in their field and know what they are investing in - doesn't stack up). Both companies have reported further advancements in their products and good results in clinical trials. In Briacell good news was followed almost immediately by an issue at significantly below the pre-news SP (a la Hemo).

Who is/are the money behind this Prevail Partners LLC fund - it's not a fund that anyone can seemingly invest in, a venture capital fund (but who funds it)?

On the plus side, on the face of it, it was an investment from venture capital. How and when are they expecting a return?

...and who (if anyone) is behind them? They have already made some chunky investments in other ventures.

Does anyone have any information relating to this Prevail managed investment "Fund"?